The EU regulatory class covering gene, tissue and cell-based medicines.
A regulatory classification (EU ATMP, advanced therapy medicinal product) for cell and gene therapies that require proof of quality, safety, and efficacy before approval. It's a gold-standard designation meaning the therapy has undergone rigorous manufacturing oversight and clinical testing. Clinics advertising "advanced therapy" products are working within regulated frameworks; clinics bypassing this classification are often operating in regulatory grey zones. Ask clinics whether their products hold ATMP designation or equivalent (FDA approval, etc.); if not, ask why and whether they're pursuing it. Lack of regulatory approval signals either early-stage research or intentional circumvention.
Medicină regenerativă certificată GMP în inima UE — de la 3.000–8.000 €, o fracțiune din prețurile din SUA sau Germania. Protocoale personalizate pentru pacienți din peste 50 de țări.
Evaluare medicală gratuită